CNSP Stock CNS Pharmaceuticals (CNSP, $4.45) Aroon Indicator entered a Downtrend on June 22, 2026.
at Tickeron.com
For the last three days, A.I.dvisor has detected that CNSP's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for CNSP, and traders may view it as a Sell signal for the next month. Traders may consider selling the stock or exploring put options. A.I.dvisor backtested this indicator and found 324 similar cases, of which were successful. Based on this data, the odds of success are
Momentum Indicator for CNSP turns negative, indicating new downward trend
CNSP saw its Momentum Indicator move below the 0 level on June 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In of the 81 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNSP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CNSP entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNSP advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .
CNSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CNSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (91.743) is normal, around the industry mean (20.966). P/E Ratio (0.003) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CNSP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.